Risperdal is a powerful antipsychotic drug that’s used to treat serious mental conditions like schizophrenia; however, allegations have arisen during a Risperdal drug injury lawsuit that the manufacturer of the drug, Johnson & Johnson (J&J), failed to disclose certain risks that were posed by taking the medication.
Attorneys for the victims argue J&J illegally marketed Risperdal to children and the elderly. This was allegedly achieved through a tactic known as “off label” marketing, a tactic of using a medication to care for a condition the U.S. Food and Drug Administration (FDA) has not approved the drug to treat.
The use of Risperdal resulted in a large number of young male patients developing gynecomastia. The condition causes male patients to develop abnormally large breast tissue and surgery is often necessary for correction.
An article from Bloomberg Business explains the victims went on to claim through the lawsuit that J& J withheld information about the risks of developing gynecomastia as a result of taking Risperdal. They claim they would have never been given or taken the drug if the risks had been known.
Even a former FDA official has come forward to support the claims that J&J’s actions resulted in a large number of patients suffering a Risperdal drug injury.
At Fleschner, Stark, Tanoos & Newlin, we understand the serious harm a medication’s side effects can have on patients. That’s why our Indiana drug injury lawyers are hopeful a decision in this particular case will bring a sense of closure to the young man who was harmed.
Fleschner, Stark, Tanoos & NewlinN/a
The financial burden that often comes with a serious injury can be too much for many people to bear. Unexpected medical debt, damaged personal property, and the sudden loss of income can impact the budgets of most families. The good news is that a successful injury claim could help reduce that financial strain after a serious accident. Get in touch with a Terre Haute personal injury lawyer with Fleschner, Stark, Tanoos & Newlin to learn more.
© Fleschner, Stark, Tanoos & Newlin